Novartis AG ADR (NVS)vsPerrigo Company PLC (PRGO)
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
PRGO
Perrigo Company PLC
$10.83
+1.50%
HEALTHCARE · Cap: $1.53B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1254% more annual revenue ($56.58B vs $4.18B). NVS leads profitability with a 23.9% profit margin vs -43.5%. PRGO appears more attractively valued with a PEG of 1.14. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
PRGO
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
+75.4%
Fair Value
$59.32
Current Price
$10.83
$48.49 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Smaller company, higher risk/reward
Operating margin of 3.5%
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PRGO
The strongest argument for PRGO centers on Price/Book. PEG of 1.14 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : PRGO
The primary concerns for PRGO are Market Cap, Operating Margin, Debt/Equity. Debt-to-equity of 1.52 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a declining stock while PRGO is a turnaround play — different risk/reward profiles.
PRGO carries more volatility with a beta of 0.54 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 45/100), backed by strong 23.9% margins. PRGO offers better value entry with a 75.4% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Perrigo Company PLC
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?